NCT00452192View on ClinicalTrials.gov

Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Metabolic Syndrome
Interventions
DRUG

Telmisartan

telmisartan 80 mg daily over 2 weeks

Trial Locations (1)

91054

Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen

All Listed Sponsors
lead

University of Erlangen-Nürnberg Medical School

OTHER

NCT00452192 - Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome | Biotech Hunter | Biotech Hunter